The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients

Clin Exp Nephrol. 2020 Apr;24(4):323-329. doi: 10.1007/s10157-019-01832-4. Epub 2019 Dec 26.

Abstract

Background: Aggregation of solid-phase calcium-phosphate and fetuin-A form nanoparticles called calciprotein particles (CPP). Serum CPP levels are increased in CKD patients and correlated with vascular stiffness and calcification. In this study, we evaluated effects of lanthanum carbonate (LC) and calcium carbonate (CC) on serum CPP levels in hemodialysis (HD) patients.

Methods: Twenty-four (24) HD patients (50% men, age; 68 ± 12 years, dialysis period; 6.2 ± 4.8 years, Kt/v; 1.74 ± 0.34) were treated with CC during 0-8 weeks and then switched to LC during 9-16 weeks. Blood samples were obtained at 0, 8, 16 weeks. Serum CPP levels (TCPP) were measured by the gel-filtration method. Low-density CPP (LCPP) levels were determined by centrifuging the serum samples at 16,000 g for 2 h and measuring CPP levels in the supernatant. The difference between TCPP and LCPP was defined as the high-density CPP (HCPP) level. We evaluated association of TCPP, LCPP, and HCPP with serum calcium (Ca), phosphorus (P), intact PTH, FGF23, Klotho, fetuin-A, aortic calcification index (ACI), LDL cholesterol, and hs-CRP.

Results: TCPP and LCPP levels were significantly decreased after switching CC to LC, whereas Ca and P levels were not changed. HCPP levels were below the lower limit quantification in all patients. The changes in P, Ca × P, LDL cholesterol, but not ACI and the changes in hs-CRP, were correlated with the change in TCPP levels.

Conclusion: The TCPP levels were significantly decreased after switching CC to LC. Non-calcium-containing phosphate binders may be preferable for lowering CPP levels.

Keywords: Calciprotein particles; Hemodialysis; Lanthanum carbonate.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Calcium / blood*
  • Calcium Carbonate / therapeutic use
  • Drug Substitution
  • Female
  • Fibroblast Growth Factor-23
  • Humans
  • Hyperphosphatemia / blood
  • Hyperphosphatemia / drug therapy*
  • Hyperphosphatemia / etiology
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy
  • Lanthanum / therapeutic use*
  • Male
  • Middle Aged
  • Phosphates / blood*
  • Prospective Studies
  • Renal Dialysis
  • alpha-2-HS-Glycoprotein / metabolism*

Substances

  • FGF23 protein, human
  • Phosphates
  • alpha-2-HS-Glycoprotein
  • lanthanum carbonate
  • Lanthanum
  • Fibroblast Growth Factor-23
  • Calcium Carbonate
  • Calcium

Grants and funding